Azetidine-substituted pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2
US-12180196-B2 · Dec 31, 2024 · US
Hormonal contraceptive containing a combination of ethinyloestradiol and chlormadinone acetate
US9107840B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9107840-B2 |
| Application number | US-936204-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 10, 2004 |
| Priority date | May 28, 2004 |
| Publication date | Aug 18, 2015 |
| Grant date | Aug 18, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a hormonal contraceptive including at least 120 hormone-containing daily units, which contain 5 to 50 μg of ethinyloestradiol and 1 to 5 mg of chlormadinone acetate, and optionally 7 to 3 hormone-free daily units for uninterrupted oral administration to women.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for the treatment of at least one of androgen-dependent symptoms, bleeding disorders, dysmenorrhoea, conditions dependent on the menstrual cycle, conditions influenced by the menstrual cycle, and premenstrual syndrome, said method comprising administering to a premenoupausal or perimenopausal woman daily units comprising a combination of ethinyloestradiol and chlormadinone acetate uninterruptedly for a duration of more than 150 days to up to 2…
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9107840B2 cover?
- The present invention relates to a hormonal contraceptive including at least 120 hormone-containing daily units, which contain 5 to 50 μg of ethinyloestradiol and 1 to 5 mg of chlormadinone acetate, and optionally 7 to 3 hormone-free daily units for uninterrupted oral administration to women.
- Who is the assignee on this patent?
- Schramm Georg, Henske Rainer, Richter Gedeon Nyrt
- What technology area does this patent fall under?
- Primary CPC classification A61K9/2866. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Aug 18 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).